<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906669</url>
  </required_header>
  <id_info>
    <org_study_id>ACTRN1261000928213</org_study_id>
    <nct_id>NCT03906669</nct_id>
  </id_info>
  <brief_title>A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.</brief_title>
  <acronym>WinPro</acronym>
  <official_title>A Window of Opportunity Study of Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Hormone Receptor-positive Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Vincent's Hospital-Manhattan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Vincent's Hospital-Manhattan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II randomised, open label study of pre-operative endocrine therapy with &amp; without
      prometrium in postmenopausal women with early stage breast hormone receptor positive (HR+)
      human epidermal receptor 2 negative (HER2-) breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is bidirectional interplay between the progesterone receptor (PR) and oestrogen
      receptor (ER) in human breast cancers. There is evidence for a reprogramming of ER chromatin
      binding sites with 470 genes differentially regulated by dual treatment with estrogen plus
      progestogen compared to estrogen alone in breast cancer cell lines. Functionally, there was
      an additive anti-cancer effect with the addition of natural progesterone to endocrine therapy
      in preclinical breast cancer models.

      This is a phase II multi-site, randomised, open-label, three-arm, study in 200 postmenopausal
      women with early-stage ER+, PR+, HER2-negative breast cancer. Eligible patients will be
      randomised (1:1:1) to receive 14 days of intervention with either letrozole 2.5mg PO daily
      (arm 1), letrozole 2.5mg + prometrium 300mg PO daily (arm 2) or tamoxifen 20mg + prometrium
      300mg PO daily (arm 3), between diagnosis of breast cancer and definitive surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean suppression of proliferation marker Ki67</measure>
    <time_frame>After two weeks of intervention, compared with baseline</time_frame>
    <description>The geometric mean suppression of the centrally assessed proliferation marker Ki67, after two weeks of intervention, compared with baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability: number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>2 years</time_frame>
    <description>Safety and tolerability of combination therapy (NCI-CTCAE v4.0)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Define a gene set as a predictive biomarker for a reduction in Ki67</measure>
    <time_frame>4 years</time_frame>
    <description>Expression of gene signature will be tested in the pre- and post-intervention tissues using the Nanostring nCounter system</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate changes in the apoptotic markers Bcl-2 and Caspase 3 in the tumors following intervention</measure>
    <time_frame>4 years</time_frame>
    <description>Immunohistochemistry of the pre and post intervention tissue samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate changes in ER, PR, AR, FoxA1, Cyclin D1 protein and mRNA expression in the tumors following intervention</measure>
    <time_frame>4 years</time_frame>
    <description>Immunohistochemistry of the pre and post intervention tissue samples</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Early-stage Breast Cancer</condition>
  <condition>Hormone Receptor Positive Tumor</condition>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Letrozole 2.5mg PO daily for 14 days between diagnosis of breast cancer and definite surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole and Prometrium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole 2.5mg PO daily and Prometrium 300mg PO daily for 14 days between diagnosis of breast cancer and definite surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamoxifen and Prometrium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamoxifen 20mg PO daily and Prometrium 300mg PO daily for 14 days between diagnosis of breast cancer and definite surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>PO daily for 14 days</description>
    <arm_group_label>Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole and Prometrium</intervention_name>
    <description>PO daily for 14 days</description>
    <arm_group_label>Letrozole and Prometrium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen and Prometrium</intervention_name>
    <description>PO daily for 14 days</description>
    <arm_group_label>Tamoxifen and Prometrium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed ER+ and PR+ breast cancer (defined as ≥10% positive staining
             cells)

          2. Histologically confirmed HER2-negative breast cancer (defined as IHC 0-1 and/or
             FISH/CISH &lt;2.2)

          3. Tumour size ≥1 cm as measured by ultrasound and/or mammogram

          4. Ability to understand all patient information and informed-consent documents, written
             informed consent to participate in the trial, and to avail tissue and blood samples
             for research

          5. Aged 18 years or older

        Exclusion Criteria:

          1. Women currently on hormone therapies, including hormone replacement therapy and oral
             contraceptive pill

          2. Locally advanced/inoperable and inflammatory breast cancer

          3. Planned for a mastectomy (due to increased risk of venous thromboembolism)

          4. Clinical evidence of metastatic disease

          5. Patients treated with other preoperative systemic therapies

          6. Nut allergy (prometrium contains peanut oil)

          7. Prior history of uterine cancer, deep vein thrombosis, pulmonary embolism or clotting
             disorder

          8. Women who are pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elgene Lim, MBBS FRACP PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Garvan Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Kent</last_name>
    <phone>+61293555611</phone>
    <email>SVHS.CancerResearch@svha.org.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kent</last_name>
      <phone>+61293555611</phone>
      <email>svhs.cancerresearch@svha.org.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D'Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS. Progesterone receptor modulates ERα action in breast cancer. Nature. 2015 Jul 16;523(7560):313-7. doi: 10.1038/nature14583. Epub 2015 Jul 8. Erratum in: Nature. 2015 Oct 1;526(7571):144. Serandour, Aurelien A A[Corrected to Serandour, Aurelien A].</citation>
    <PMID>26153859</PMID>
  </reference>
  <reference>
    <citation>Lim E, Tarulli G, Portman N, Hickey TE, Tilley WD, Palmieri C. Pushing estrogen receptor around in breast cancer. Endocr Relat Cancer. 2016 Dec;23(12):T227-T241. Epub 2016 Oct 11. Review.</citation>
    <PMID>27729416</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>April 5, 2019</last_update_submitted>
  <last_update_submitted_qc>April 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St Vincent's Hospital, Sydney</investigator_affiliation>
    <investigator_full_name>Elgene Lim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>early stage breast cancer</keyword>
  <keyword>prometrium</keyword>
  <keyword>progesterone</keyword>
  <keyword>post-menopausal</keyword>
  <keyword>endocrine therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

